A pseudogene-signature in glioma predicts survival

Journal of Experimental & Clinical Cancer Research

Yong-Ping You¹  Wei Yan¹  Yingyi Wang¹  Jun-xia Zhang¹  Xin-cheng Chen¹  Kai-Ming Gao¹ 

[1] Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

关键词: Biomarker;    Survival;    Glioma;    Pseudogene;   

Others  :  1145666
DOI  :  10.1186/s13046-015-0137-6

 received in 2014-10-10, accepted in 2015-02-16,  发布年份 2015

【 摘 要 】

Pseudogene was recognized as a potential tumor suppressor or oncogene in varies of diseases, however its roles in glioma have not been investigated. Our study was to identify the pseudogene-signature that predicted glioma survival. Using a pseudogene-mining approach, we performed pseudogene expression profiling in 183 glioma samples from the Chinese Glioma Genome Atlas (CGGA) and set it as the training set. We found a six-pseudogene signature correlated with patients’ clinical outcome via bioinformatics analyses (P ≤ 0.01), and validated it in the Repository of Molecular Brain Neoplasia Data (REMBRANDT) containing 350 cases. A formula calculating the risk score based on the six-pseudogene signature was introduced and the patients of CGGA set were classified into high-risk group and low-risk group with remarkably different survival (P < 0.001) based on their scores. The prognostic value of the signature was confirmed in the REMBRANDT set. Though the function of these pseudogenes is not clear, the identification of the prognostic pseudogenes indicated the potential roles of pseudogenes in glioma pathogenesis and they may have clinical implications in treating glioma.

【 授权许可】

   
2015 Gao et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, et al.: Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 2009, 18(8):1061-83.
• [2]Li R, Gao K, Luo H, Luo H, Wang X, Shi Y, et al.: Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res 2014, 33:9. BioMed Central Full Text
• [3]Zhang XQ, Sun S, Lam KF, Kiang KMY, Pu JKS, Ho ASW, et al.: A long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol Dis 2013, 58:123-31.
• [4]Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson M, et al.: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17(1):98-110.
• [5]Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY: Primary brain tumours in adults. Lancet 2012, 379(9830):1984-96.
• [6]Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H, et al.: Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011, 146(2):209-21.
• [7]Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al.: Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008, 26(18):3015-24.
• [8]Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y: Analysis of gene expression data using BRB-ArrayTools. Cancer Informat 2007, 3:11-7.
• [9]Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al.: Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011, 118(5):1350-8.
• [10]Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350(18):1828-37.
• [11]Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al.: Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res 2004, 64(7):2357-64.
• [12]Edgar AJ: The human L-threonine 3-dehydrogenase gene is an expressed pseudogene. BMC Genet 2002, 3:18. BioMed Central Full Text
• [13]Jia JW, Li KL, Wu JX, Guo SL: Clinical significance of annexin II expression in human non-small cell lung cancer. Tumour Biol 2013, 34(3):1767-71.
• [14]Zhang HJ, Yao DF, Yao M, Huang H, Wang L, Yan MJ, et al.: Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells. World J Gastroenterol 2013, 19(24):3792-801.
• [15]Demeure MJ, Coan KE, Grant CS, Komorowski RA, Stephan E, Sinari S, et al.: PTTG1 overexpression in adrenocortical cancer is associated with poor survival and represents a potential therapeutic target. Surgery 2013, 154(6):1405-16. discussion 16
• [16]Jia W, Lu R, Jia G, Ni M, Xu Z: Expression of pituitary tumor transforming gene (PTTG) in human pituitary macroadenomas. Tumour Biol 2013, 34(3):1559-67.
• [17]Sasaki Y, Koyama R, Maruyama R, Hirano T, Tamura M, Sugisaka J, et al.: CLCA2, a target of the p53 family, negatively regulates cancer cell migration and invasion. Cancer Biol Ther 2012, 13(14):1512-21.
• [18]Walia V, Yu Y, Cao D, Sun M, McLean JR, Hollier BG, et al.: Loss of breast epithelial marker hCLCA2 promotes epithelial-to-mesenchymal transition and indicates higher risk of metastasis. Oncogene 2012, 31(17):2237-46.
• [19]Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, et al.: Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler, Thromb, Vasc Biol 2013, 33(12):2902-8.
• [20]Anderson JL, Knight S, May HT, Horne BD, Bair TL, Huntinghouse JA, et al.: Validation and quantification of genetic determinants of lipoprotein-a levels and predictive value for angiographic coronary artery disease. Am J Cardiol 2013, 112(6):799-804.